Interpace Biosciences, Inc. (IDXG): Price and Financial Metrics

Interpace Biosciences, Inc. (IDXG): $8.18

-0.03 (-0.37%)

POWR Rating

Component Grades













IDXG Stock Summary

  • IDXG has a market capitalization of $33,759,972 -- more than approximately merely 6.97% of US stocks.
  • The capital turnover (annual revenue relative to shareholder's equity) for IDXG is -1.11 -- better than just 4.69% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -5.98 for Interpace Biosciences Inc; that's greater than it is for just 2.73% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Interpace Biosciences Inc are KIDS, SREV, ADMS, CCF, and TREE.
  • IDXG's SEC filings can be seen here. And to visit Interpace Biosciences Inc's official web site, go to

IDXG Stock Price Chart Interactive Chart >

Price chart for IDXG

IDXG Price/Volume Stats

Current price $8.18 52-week high $8.50
Prev. close $8.21 52-week low $2.57
Day low $8.14 Volume 5,243
Day high $8.30 Avg. volume 170,154
50-day MA $5.29 Dividend yield N/A
200-day MA $4.27 Market Cap 33.64M

Interpace Biosciences, Inc. (IDXG) Company Bio

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

IDXG Latest News Stream

Event/Time News Detail
Loading, please wait...

IDXG Latest Social Stream

Loading social stream, please wait...

View Full IDXG Social Stream

Latest IDXG News From Around the Web

Below are the latest news stories about Interpace Biosciences Inc that investors may wish to consider to help them evaluate IDXG as an investment opportunity.

Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®

Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis (PLA) code that specifically identifies ThyGeNEXT® as a distinct test from any other test or service. PLA codes are an addition to the current procedural terminology (CPT®) code set approved by the American Medical Association CPT® Editorial Panel. PLA codes are alpha-numeric CPT codes with a corresponding descriptor for labs that want to more specifically identify their test. The new PLA code for ThyGeNEXT® is 0245U and the reimbursement for this code remains $2,919, representing a significant price increase over the prior reimburse...

Yahoo | April 5, 2021

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR

Part of Company’s Site Consolidation and Cost Savings Measures Parsippany, NJ, March 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into a definitive agreement to sell its New Haven CT CLIA certified, CAP accredited laboratory to DiamiR Biosciences, Corp. (DiamiR). This sale is in line with previously announced restructuring and cost reduction initiatives announced by Interpace. Under this agreement, DiamiR will provide overflow lab testing in support of the Company’s molecular thyroid testing products at its main laboratory in Pittsburgh, PA. DiamiR will also support specific Interpace assay development and validation services on behalf of the Company for the next three quarters. Subject to specific terms and conditions of the a...

Yahoo | March 17, 2021

Interpace Biosciences Announces Impending Delisting from Nasdaq

PARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on February 16, 2020 it had received notification from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff has determined to delist the Company’s securities from Nasdaq. This determination was due to the Company’s extended period of non-compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in listing Rule 5550(b) and the Company’s failure to timely execute on its plan to comply. Unless the Company requests an appeal of this determination, trading of the Company’s common stock will be suspended at the...

Yahoo | February 17, 2021

Interpace Biosciences Announces Path Forward in Letter to Shareholders

PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareholders: Dear Shareholders, As the newly appointed President and CEO of Interpace I want to take a moment to formally introduce myself and share the new vision and mission for this Company as it relates to our core capabilities, growth prospects and directional outlook for this year and beyond. I joined Interpace with significant leadership experience, including with several specialty clinical laboratories. This includes serving as President & CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories and Eurofins Scientific, Inc. I bring to the table important experience in developing and implem...

Yahoo | February 17, 2021

Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital

Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, used in the risk assessment of pancreatic cysts. Although some cysts may have no cancerous potential at all, other cysts carry up to a 48 percent chance of harboring invasive cancer, and surgery to remove them is often complex. Therefore, there is a need to develop additional tools to identify which pancreatic cysts may develop into cancer and which ones will not. In a recent, national multicenter study of patients undergoing surgery for pancreatic cysts, the Das-1 antibody was able to accurately identify pa...

Yahoo | February 1, 2021

Read More 'IDXG' Stories Here

IDXG Price Returns

1-mo 60.39%
3-mo 99.51%
6-mo 103.99%
1-year 50.92%
3-year -9.61%
5-year -84.85%
YTD 160.51%
2020 -37.20%
2019 -37.50%
2018 -21.57%
2017 -76.82%
2016 -6.38%

Continue Researching IDXG

Want to see what other sources are saying about Interpace Biosciences Inc's financials and stock price? Try the links below:

Interpace Biosciences Inc (IDXG) Stock Price | Nasdaq
Interpace Biosciences Inc (IDXG) Stock Quote, History and News - Yahoo Finance
Interpace Biosciences Inc (IDXG) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1209 seconds.